Overall, these results suggest that the pan-HDACi belinostat may have activity in high-grade glial neoplasms, which warrants further testing of this drug, and that IDH mutational status may serve as a biomarker of response to HDAC inhibition. This evidence concerns the gene IDH1 and glioma.